Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydrex is a topical antiseptic solution containing 0.5% chlorhexidine gluconate (CHG) and 70% isopropyl alcohol (IPA). Developed by Enturia, Inc. (now part of BD), it is primarily indicated for pre-operative skin antisepsis and post-operative wound care to reduce skin bacterial counts and prevent surgical site infections (SSIs). The formulation leverages the synergistic antimicrobial properties of its two active components: chlorhexidine gluconate provides persistent activity by disrupting microbial cell membranes, while isopropyl alcohol offers rapid bactericidal action by denaturing proteins. Hydrex has been evaluated in Phase 4 clinical trials, particularly in the United Kingdom, where its efficacy in reducing bacterial counts and infection rates was compared against higher-concentration formulations such as ChloraPrep (2% CHG) in patients undergoing coronary artery bypass grafting (CABG).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorhexidine gluconate + isopropyl alcohol.